REPORTS

Let’s Pullulate and Expand Your Business

Postmenopausal Vaginal Atrophy Drugs Market - Global Professional Analysis and Forecast to 2026

Mar 05, 2020  |  184 PAGES  |  REPORT CODE: CMM270196
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Postmenopausal Vaginal Atrophy Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period.

This report presents the market size and development trends by detailing the Postmenopausal Vaginal Atrophy Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Postmenopausal Vaginal Atrophy Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Postmenopausal Vaginal Atrophy Drugs industry and will help you to build a panoramic view of the industrial development.

Postmenopausal Vaginal Atrophy Drugs Market, By Type:

  • Premarin

  • Vagifem

  • Estrace

  • Estring

  • Femring

Postmenopausal Vaginal Atrophy Drugs Market, By Application:

  • Vaginal Gels

  • Creams

  • Tablets

  • Rings

  • Patches

Some of the leading players are as follows:

  • Pfizer Inc.

  • Bionovo, Inc.

  • Therapeutics MD, Inc.

  • Shionogi & Company

  • Actavis plc

  • Shionogi & Co. Ltd.

  • Teva Pharmaceuticals Ltd.

  • Endoceutics, Inc.

  • Allergan plc

  • Novo Nordisk A/S

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Postmenopausal Vaginal Atrophy Drugs Market: Technology Type Analysis

  • 4.1 Postmenopausal Vaginal Atrophy Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Postmenopausal Vaginal Atrophy Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Premarin

    • 4.3.2 Vagifem

    • 4.3.3 Estrace

    • 4.3.4 Estring

    • 4.3.5 Femring

5 Postmenopausal Vaginal Atrophy Drugs Market: Product Analysis

  • 5.1 Postmenopausal Vaginal Atrophy Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Postmenopausal Vaginal Atrophy Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Postmenopausal Vaginal Atrophy Drugs Market: Application Analysis

  • 6.1 Postmenopausal Vaginal Atrophy Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Postmenopausal Vaginal Atrophy Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Vaginal Gels

    • 6.3.2 Creams

    • 6.3.3 Tablets

    • 6.3.4 Rings

    • 6.3.5 Patches

7 Postmenopausal Vaginal Atrophy Drugs Market: Regional Analysis

  • 7.1 Postmenopausal Vaginal Atrophy Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Postmenopausal Vaginal Atrophy Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Pfizer Inc.

    • 9.1.1 Pfizer Inc. Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Bionovo, Inc.

    • 9.2.1 Bionovo, Inc. Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Therapeutics MD, Inc.

    • 9.3.1 Therapeutics MD, Inc. Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Shionogi & Company

    • 9.4.1 Shionogi & Company Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Actavis plc

    • 9.5.1 Actavis plc Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Shionogi & Co. Ltd.

    • 9.6.1 Shionogi & Co. Ltd. Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Teva Pharmaceuticals Ltd.

    • 9.7.1 Teva Pharmaceuticals Ltd. Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Endoceutics, Inc.

    • 9.8.1 Endoceutics, Inc. Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Allergan plc

    • 9.9.1 Allergan plc Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Novo Nordisk A/S

    • 9.10.1 Novo Nordisk A/S Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

 

The List of Tables and Figures (Totals 87 Figures and 129 Tables)

  • Figure Premarin Postmenopausal Vaginal Atrophy Drugs market, 2015 - 2026 (USD Million)

  • Figure Vagifem Postmenopausal Vaginal Atrophy Drugs market, 2015 - 2026 (USD Million)

  • Figure Estrace Postmenopausal Vaginal Atrophy Drugs market, 2015 - 2026 (USD Million)

  • Figure Estring Postmenopausal Vaginal Atrophy Drugs market, 2015 - 2026 (USD Million)

  • Figure Femring Postmenopausal Vaginal Atrophy Drugs market, 2015 - 2026 (USD Million)

  • Figure Vaginal Gels market, 2015 - 2026 (USD Million)

  • Figure Creams market, 2015 - 2026 (USD Million)

  • Figure Tablets market, 2015 - 2026 (USD Million)

  • Figure Rings market, 2015 - 2026 (USD Million)

  • Figure Patches market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Postmenopausal Vaginal Atrophy Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Postmenopausal Vaginal Atrophy Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Postmenopausal Vaginal Atrophy Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Postmenopausal Vaginal Atrophy Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Postmenopausal Vaginal Atrophy Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Postmenopausal Vaginal Atrophy Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Postmenopausal Vaginal Atrophy Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Pfizer Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bionovo, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Therapeutics MD, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Shionogi & Company Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Actavis plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Shionogi & Co. Ltd. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Teva Pharmaceuticals Ltd. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Endoceutics, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novo Nordisk A/S Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top